The Dose Ledger
Retatrutide trial doses, read closely. An independent editorial project.
About

About this site: one molecule, its trial doses, nothing else

retatrutidedose.com is an independent editorial project with a single subject: the doses of retatrutide used in published clinical trials, and what each dose produced. It is written for people who want the numbers with their sources, not a protocol.

Published 21 Sept 2026Contact editor@retatrutidedose.com
A wooden desk with an open notebook, reading glasses and a cup of green tea by a white wall

What we publish

Retatrutide is an investigational triple agonist with a small, well-defined literature: a phase 1 paper in Cell Metabolism, a phase 1b trial in The Lancet, two phase 2 trials in the NEJM and The Lancet, substudies in Nature Medicine and The Lancet Diabetes and Endocrinology, a phase 3 design paper, and the first phase 3 results in The Lancet in 2026.

Every dose with human data lives in those papers and in the ClinicalTrials.gov entries behind them. This site reads them closely and lays out the doses, schedules, escalation and results in plain English, with the source next to each figure.

The home page, the retatrutide dosage guide, is the summary. The guides under it each take one question (schedule, reconstitution, half-life, cycle length, titration, vial sizes, comparison with tirzepatide, diabetes doses, the phase 3 program) and answer it from the same sources.

How a number gets on the site

Each figure passes three checks before publication. First, it is read from the primary publication or the registry entry, not from a secondary summary. Second, the DOI is resolved on CrossRef and the NCT number on ClinicalTrials.gov on the day of writing; a source that does not resolve is not cited.

Third, the figure is written with its context: population, dose, time point, comparator. A weight change without its week, or a dose without its starting dose, is not a fact about retatrutide, it is a fragment.

Where the papers are silent, the site says so rather than filling the gap. The intermediate steps of the phase 3 escalation, missed-dose rules and off-treatment outcomes are examples: each page that touches them states that no published figure exists.

Sources that qualify

Only two kinds of source are used for numbers:

  • peer-reviewed publications with a DOI that resolves on https://api.crossref.org, and
  • trial registrations on https://clinicaltrials.gov, identified by NCT number.

Press releases, conference abstracts without a paper, news coverage, forum posts and supplier claims are not used for numbers. The full list of sources cited across the site:

  1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. doi.org/10.1056/NEJMoa2301972
  2. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet. 2023;402(10401):529-544. doi.org/10.1016/S0140-6736(23)01053-X
  3. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet. 2022;400(10366):1869-1881. doi.org/10.1016/S0140-6736(22)02033-5
  4. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234-1247. doi.org/10.1016/j.cmet.2022.07.013
  5. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. doi.org/10.1038/s41591-024-03018-2
  6. Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The Lancet Diabetes and Endocrinology. 2025. doi.org/10.1016/S2213-8587(25)00092-0
  7. Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. The Lancet. 2026;407(10546):2402-2413. doi.org/10.1016/S0140-6736(26)00967-0
  8. Giblin A, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, Obesity and Metabolism. 2025;28:83-93. doi.org/10.1111/dom.70209
  9. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216. doi.org/10.1056/NEJMoa2206038
  10. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. doi.org/10.1001/jama.2023.24945
  11. ClinicalTrials.gov. A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight. Completed; 338 participants. clinicaltrials.gov/study/NCT04881760
  12. ClinicalTrials.gov. A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes. Completed; 281 participants. clinicaltrials.gov/study/NCT04867785
  13. ClinicalTrials.gov. TRIUMPH-1: retatrutide once weekly in participants without type 2 diabetes who have obesity or overweight. Phase 3; 2,335 participants; primary endpoint at week 80. clinicaltrials.gov/study/NCT05929066
  14. ClinicalTrials.gov. TRIUMPH-2: retatrutide once weekly in participants with type 2 diabetes who have obesity or overweight. Phase 3; 1,152 participants; primary endpoint at week 80. clinicaltrials.gov/study/NCT05929079
  15. ClinicalTrials.gov. TRIUMPH-3: retatrutide once weekly in participants with severe obesity and established cardiovascular disease. Phase 3; 1,946 participants; primary endpoint at week 80. clinicaltrials.gov/study/NCT05882045
  16. ClinicalTrials.gov. TRIUMPH-4: retatrutide once weekly in participants with obesity or overweight and knee osteoarthritis. Phase 3; 445 participants; primary endpoints at week 68. clinicaltrials.gov/study/NCT05931367
  17. ClinicalTrials.gov. TRANSCEND-T2D-1: retatrutide once weekly compared with placebo in adults with type 2 diabetes on diet and exercise alone. Phase 3; 537 participants; 40 weeks. clinicaltrials.gov/study/NCT06354660

What we do not do

  • No personal dosing advice. The doses here are trial doses, reported; they are not recommendations.
  • No testimonials, reviews or anecdotes. Individual reports are not evidence about a dose.
  • No sales. The site does not sell anything and has no shopping cart.
  • No tracking. There is no analytics script, no advertising pixel, no cookie banner because there is nothing to consent to.
  • No newsletter, no pop-ups, no forms.

Each page carries a text link to a single research supplier listing, marked "research use only". The site is supported by that relationship. It does not change what the trials reported: every number is taken from the paper or registry named next to it, and the pages would read the same without the link. Readers who follow it are leaving an informational site for a commercial one, and the disclaimer at the foot of every page applies.

Corrections

If a figure on this site does not match its source, write to editor@retatrutidedose.com with the page and the discrepancy. Corrections are made on the page, the "updated" date is changed, and material changes are noted at the foot of the page concerned. New peer-reviewed retatrutide dose data, in particular the TRIUMPH phase 3 publications, will be added when it carries a DOI. The rules in full are in the editorial policy.